Role of noradrenergic fibers of the preoptic area in regulating sleep.
The preoptic area (POA) has noradrenergic (NE) terminals, and this area controls sleep apart from body temperature and reproduction. The destruction of catecholaminergic (CA) terminals in the POA produced a decrease in sleep in rats. This effect was shown to be due to the destruction of NE and not dopaminergic terminals. The rats, which were hyperthermic after the destruction of CA fibers in the POA, preferred a lower ambient temperature. Though they were unable to have normal amount of sleep after lesion, it did not affect their behavioral thermoregulation. Acute total sleep deprivation for 48 h led to a significant decrease in noradrenaline, increase in the level of metabolites of monoamines, and an enhancement in the number of dendritic spines at the medial preoptic area (mPOA). Enhanced sleep pressure during sleep deprivation could have led to a higher release of noradrenaline, and an increase in dendritic spines in the mPOA. Arousal was produced by application of noradrenaline at the mPOA, whereas the alpha antagonists produced sleep in free-moving rats. This was in contrast to the increased wakefulness produced by the destruction of NE terminals. As wakefulness and sleep, respectively, were induced on local application of alpha-2 antagonist and agonists, it was suspected that the noradrenaline and alpha antagonists might have acted on the alpha-2 receptors, which are predominantly present on the pre-synaptic terminals. Sleep produced by noradrenaline, which was locally applied at the mPOA, after destroying the NE terminals, further confirmed this possibility. Hypothermia and sexual arousal produced by application of alpha- and beta-adrenergic agonists at the mPOA would have contributed towards the wakefulness induced by these drugs in normal rats. Thus, the available evidence shows that the NE fibers in the POA are involved in the induction of sleep.
Department of Physiology, All India Institute of Medical Sciences, 110029 New Delhi, India.
Velayudhan Mohan
VM
Kumar
D000322:Adrenergic Agonists / Q000494:pharmacology; D018674:Adrenergic Antagonists / Q000494:pharmacology; D000320:Adrenergic Fibers / Q000502:physiology*; D000818:Animals; D001831:Body Temperature / Q000502:physiology; D003712:Dendrites / Q000502:physiology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D008297:Male; D009411:Nerve Endings / Q000502:physiology; D009638:Norepinephrine / Q000502:physiology*; D011301:Preoptic Area / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D012726:Sexual Behavior, Animal / Q000502:physiology; D012890:Sleep / Q000502:physiology*; D012892:Sleep Deprivation; D014851:Wakefulness / Q000502:physiology
D000322:Adrenergic Agonists; D018674:Adrenergic Antagonists; D009638:Norepinephrine